PHYSICIANS now have access to Rx product data in an intelligent, natural way with a super-powered prior authorization platform

Until now, physicians have had to hunt through websites that unfortunately are not focused on user experience to get drug product data they need to treat their patients.

Issues:

  • Costs hours to research - and increases staff and physician administrative burden.

  • Directly affects patient care.

  • Always concerned about data accuracy and relevance to their specific issue.

Not anymore. Enter EINSTEIN™, by GENIUS. A complete physician AI-powered clinical drug assistant that:

  • Includes the most advanced global data of every FDA drug (100k+ labels updated daily).

  • Directly trained on physician’s clinical EHR.

  • Understands pharmacology, adverse effects, conditions, contraindications, black-box warnings, drug allergies, and drug-drug interactions.

The true top-of-the-mind effect is achieved because the relevant data is provided at the time and at the location where it’s needed.

Meet EINSTEIN™ -

your on-demand clinical team

With EINSTEIN™, GENIUS’ intuitive clinical reasoning AI platform, physicians now have an extended “team” that provides:

  1. An immediate and complete repository of all global FDA drug label data, including the latest pharma clinical studies with citations for audit, is updated daily to allow for DDI, allergies, co-morbidities, and black-box warnings against suggested new drug regimens.

  2. Patient-specific EHR records with lab values and patient adherence monitoring to cross reference - sent back and forth via our proprietary X12 health data adjudication “highway” to payers.

  3. Payers’ PA process is reliable and justifiable.

EINSTEIN™ is a true self-serve platform that operates within the clinic and extends to all payers.

The most advanced global fda Drug data on-demand

With more than 2 million scientific journals published each year, keeping up with the latest biomedical information can feel impossible. GENIUS’ EINSTEIN™ is updated daily by our science team, and our platform reveals intelligent drug data at the time of need for evaluating a patient’s new drug regimen.

  • This provides a comprehensive list of all approved drugs, detailed molecular descriptions, and comprehensive nomenclature and identifiers

  • Helps uncover new insights for drug discovery and repurposing. Some effects can even turn into new indications.

  • Includes cross-sensitivities information with overview, and description, potential sensitive drugs, and incidence rates.

  • Helpful for knowing when a drug should not be prescribed, as well as for discovery work and pharmacovigilance for risk assessment.

  • Search by the medical condition you are looking to treat or return conditions based on a drug. Get condition-specific descriptors which include:

    ■ Severity

    ■ Status

    ■ Stage of a condition or disease

  • Helpful for risk assessment and enables healthcare providers to make better-informed decisions when prescribing.

  • Most use cases benefit from indication data as it is critical to have an understanding of a drug’s on-label and off-label uses.

  • EINSTEIN™ has the most robust of its kind in the world and is beneficial for a wide range of uses, including risk assessments for new drug regimens.

What’s included:

EINSTEIN™ also helps with the exhaustive burden of prior authorization

The use of AI bot-to-bot or “battle of the bots” is a stop-gap solution. It’s like building a truck instead of using a highway. GENIUS’ interoperable end-to-end platform is the latter.

Physicians struggle with intelligent and actionable data because of a lack of interoperability and disconnected sources and systems. This makes it nearly impossible to navigate Rx prior authorization because no one is talking to each other. It's a huge pain point and a massive burden on physicians, patients, and even payers.

“Prior authorization has in fact interfered with a patient’s job responsibilities, according to a majority of physicians (51%) who participated in a newly released AMA survey (PDF) of 1,004 physicians who treat active members of the workforce.

“Health insurance companies entice employers with claims that prior authorization requirements keep health care costs in check, but often these promises obscure the full consequences on an employer’s bottom line or employees’ well-being,” said AMA President Gerald E. Harmon, MD.

On top of using PAs, there is the use of step-therapy. Step therapy is a process by which insurers (public or private) require patients to take one or more alternative medications before they can access the medicine prescribed by their provider.

How it works: Patients must try less expensive medications before they can access more expensive ones. Patients and their doctors must document unsuccessful attempts at treatment with the less expensive options. Prevalence: A 2021 review found that 38.9% of drug coverage policies used step therapy.

Challenges: Step therapy can frustrate patients, especially those with serious or chronic conditions. It can also add administrative complexity to the HCP and staff.

Impact Calculator

Calculate how EINSTEIN™ can benefit your clinic or healthcare system.

More than one-third (34%) of physicians reported that prior authorization led to a serious adverse event. This includes hospitalization (24%), and disability or even death (8%) for a patient in their care.

Meanwhile, 30% of physicians reported that prior authorization criteria are rarely or never evidence-based, with 91% saying prior authorization has a somewhat or significant negative impact on patients’ clinical outcomes.

Source: AMA

Why the EINSTEIN™ co-clinician makes a difference in patient care and in saving time.

“With a massive proliferation of new types of data to support existing treatments, healthcare practitioners and patients have access to 75 percent more assets per indication than they did ten years ago.

With more therapeutic options available, staying current with scientific literature and guidelines has become an overwhelming task for community and academic physicians.”

— McKinsey, “A vision for medical affairs 2030”

See how GENIUS, a fully interoperable suite of enterprise-level AI platforms, can transform the relationship between patients, physicians, payers, and pharma.